Does Pluvicto improve quality of life compared to switching androgen receptor pathway inhibitors in patients with progressive metastatic prostate cancer?
What proportion of patients were still on their original regimen of endocrine therapy and CDK4/6 inhibitor at 12 months following SBRT to sites of oligoprogression on the AVATAR trial?
In the VERITAS trial, what was the rate of pneumothorax after nav bronch versus needle biopsy for lung nodules?
Does regional nodal irradiation increase recurrence free survival in clinically node positive breast cancer patients who have a complete response to neoadjuvant systemic therapy?
Answers
Yes. QOL outcomes from the PSMAfore trial showed significant delay in worsening of QOL domains.
44%. At 24 months, 36% were still on their original regimen. Local control of irradiated sites was 100%.
3.3% v 28.3%. Nav bronch had non-inferior diagnostic accuracy (79% v 73.6%).
No. In NSABP B-51, RNI did not improve outcomes in those who have a nodal pCR. Up for debate is a potential benefit from RNI among the subset with HR+/HER2- disease. | QuadShot News
What proportion of patients were still on their original regimen of endocrine therapy and CDK4/6 inhibitor at 12 months following SBRT to sites of oligoprogression on the AVATAR trial?
In the VERITAS trial, what was the rate of pneumothorax after nav bronch versus needle biopsy for lung nodules?
Does regional nodal irradiation increase recurrence free survival in clinically node positive breast cancer patients who have a complete response to neoadjuvant systemic therapy?
Answers
Yes. QOL outcomes from the PSMAfore trial showed significant delay in worsening of QOL domains.
44%. At 24 months, 36% were still on their original regimen. Local control of irradiated sites was 100%.
3.3% v 28.3%. Nav bronch had non-inferior diagnostic accuracy (79% v 73.6%).
No. In NSABP B-51, RNI did not improve outcomes in those who have a nodal pCR. Up for debate is a potential benefit from RNI among the subset with HR+/HER2- disease. | QuadShot News